Steering through Regulatory Currents: The Journey of India’s Pharma Industry with the USFDA
Introduction and Objective: India's pharmaceutical industry faces challenges in meeting USFDA quality standards, impacting exports and reputation. This review examines the causes of non-compliance and proposes strategies to enhance compliance, predicting fu-ture trends. Methods: This study conducts an analysis of USFDA warning letters to Indian manufacturers, an assessment of non-compliance issues, and an exploration of technological advancements in compliance, such as automation and AI. Results: The study reveals a rise in non-compliance incidents, emphasizing the need for a ro-bust quality culture, updated regulatory knowledge, and implementation of advanced technol-ogies to improve compliance. Conclusion: To maintain global competitiveness, India's pharma industry must adopt compre-hensive strategies, leverage technology, and prepare proactively for regulatory changes. Future compliance will rely on remote auditing and real-time monitoring.
Authors
- Diksha Diksha (ORCID: https://orcid.org/0009-0005-4276-5495)
- Raj Kamal (ORCID: https://orcid.org/0000-0002-7138-6313)
- Ankit Awasthi (ORCID: https://orcid.org/0000-0002-3266-7649)
- Priyanka Paul
Institutions
- Indo Soviet Friendship College of Pharmacy (IN)
Publication Details
- Journal
- Applied Drug Research Clinical Trials and Regulatory Affairs
- Published
- 2024-09-20
- DOI
- https://doi.org/10.2174/0126673371310378240808054710
- Primary Topic
- Indian Economic and Social Development
- Type
- article
- Field-Weighted Citation Impact
- 0.00